The psychopharmacological era in psychiatry started with the introduction of chlorpromazine in the early 1950s. The important role played by neuroleptic drugs in the subsequent changes in management of the chronic schizophrenic patient and in the outlook on his social prognosis is almost generally recognized.
Kline's graphic demonstration presented at the American College of Neuropsychopharmacology of the decreasing number of resident patients in State and Local Government mental hospitals in the United States during the decade 1956-67 can quite clearly be interpreted as the effect of the widespread use of psychopharmaceutical drugs.
Similar figures, maybe not quite as convincing, have been published elsewhere. In Denmark, comprehensive census studies in 1957 , 1962 and 1967 (Juel-Nielsen & Stromgren 1969 showed that whereas the total number of resident patients was about the same, a marked change in the diagnostic distribution had occurred, to the effect that there was a spectacular decrease in the number of schizophrenics (especially female) while the number with senile and cerebrovascular psychoses and of manic-depressive illness had increased.
In both Nordic and German studies (Odegard 1963 , Lauber 1964 it is emphasized that the reduction of the schizophrenic hospital population is the result of a shorter duration of each inpatient period, but that on the other hand a conspicuous increase in the number of readmissions has occurred, giving birth to the concept of 'revolving door patient'. This concept should not be used only in a disparaging way, but rather looked upon as an incentive to further development of more efficient after-care measures; parttime hospitalizations; day hospitals; sheltered workshops; patient clubs and so on. These and other psychosocial therapeutic activities are all important factors in the attempts at rehabilitation or resocialization of the chronic schizophrenic patient.
How do the neuroleptic drugs now fit into this therapeutic pattern? To answer this question it may be useful to look at the classification of
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ChiefPsychiatrist, Sankt Hans Hospital, Roskilde, Denmark neuroleptics. Chemical and pharmacological classifications have been made, but they are of limited value from the clinical point of view. Various clinical classification models have been suggested, most of them of the bipolar type such as the one constructed by one of us (Kristjansen 1974) , comprising the most widely used of the neuroleptics put on the market in Scandinavia (Fig 1) . In a classification of this type the neuroleptic drugs are divided into those given in high dosages and having pronounced sedative and anxiolytic effect and, via a middle group, those which are effective at a low dosage level and possess more specific antipsychotic properties. Bobon and Collard's classification model (Collard 1974 ) is based on another principle and deserves special attention ( Fig 2) . As you. notice from the physiognomy of neuroleptics described by the author, both clinical and pharmacological properties are included in the model, so that it may be possible from a clinical analysis of a patient's dominating symptoms to point out the 'drug of choice' for just this patient, or at any rate the type of drug to be preferred in the longterm treatment of schizophrenic patients of various symptomatology.
In our departments we feel that the specific, low dosage, non-sedative neuroleptics are to be preferred in the long-term treatment of schizophrenia. Quite often they can be administered only once a daymorning or evening, according to preference. This type of administration is frequently more acceptable to the patient, which is important considering the fact that nearly half of the schizophrenic outpatients are unreliable medicine-takers after discharge from hospital. Long-acting drugs whether given as depotinjections or orally administered may be the best solution in these cases, but there are patients who either refuse this kind of treatment or do not respond in a satisfactory way.
As already mentioned, it is generally an advantage to use low dosages of a specific antipsychotic drug in the long-term treatment of schizophrenia and if possible only one drug to each patient. Psychopharmacological cocktails should be avoided, with the exception that sometimes it may be necessary to add an unspecific neuroleptic drug for sleeping disorders or in periods of exacerbation.
As a general rule one should endeavour to give a drug treatment which (with a minimum of sideeffects) will reduce psychotic symptoms without interfering with normal behaviour. It should prevent neither spontaneous remissions nor the rehabilitating effect of psychosocial measures.
Drug-induced reversible extrapyramidal reactions are common but far from universal in relation to treatment with neuroleptic drugs. The incidence in 3775 patients is shown by Ayd (1973, Fig 3) . Anti-parkinsonian drugs are still widely used in ro6tine association with neuroleptics, in spite of repeated admonitions from authoritative sources that this should not be done.
It has been shown that the concentration of chlorpromazine in plasma decreases under antiparkinsonian treatment (Lader 1975) and animal experiments from various laboratories including our own have clearly suggested an antagonistic effect of the anti-parkinsonian agents to the antipsychotic effect of the neuroleptics (Fog 1972) . This suggestion has been confirmed by a number of clinical investigators from Haase (1966) to Lehmann (1974 (Di Mascio 1974) . The fact that some patients apparently become dependent or even addicted to anti-parkinsonian drugs due to their slight euphorizing effect should not be forgotten in this connexion. In our opinion it is not only unnecessary but a genuine therapeutic mistake to combine neuroleptic and, antiparkinsonian treatment as a routine prophylactic measure.
If extrapyramidal side-effects appear during neuroleptic maintenance treatment, they may be relieved by drug-reduction or association of an anti-parkinsonian drug for a short period only. Acute dystonic reactions should of course be treated at once by intramuscular or intravenous injections of an anti-parkinsonian drug.
Tardive dyskinesia produced by prolonged administration of neuroleptics in unnecessarily high dosage is a serious problem in long-term treatment and is sometimes irreversible. It is a syndrome consisting of coordinated involuntary stereotyped and rhythmic movements of choreiform type, mainly located to the facial, mandibular and lingual muscles, the so-called buccolingual-mandibular syndrome.
Anti-parkinsonian agents tend to increase the symptoms of tardive dyskinesia and should be discontinued at once. The only relevant corrective treatment so far is effected by drugs with antidopaminergic properties such as pimozide and tetrabenazine. There is a clear and rational pharmacological background for this statement. Treatment of tardive dyskinesia with drugs either inhibiting the uptake of dopamine by the dopamine granule in the bouton (tetrabenazine, reserpine) or increasing the sensitivity of the receptor membrane to dopamine (haloperidol, pimozide) has been suggested and used during the last decade with good results (Fog & Pakkenberg 1970) , but to treat tardive dyskinesia with anti-parkinsonian agents is, in our opinion, not only useless, but may even be injurious to the patients.
In a considerable number of studies, psychopharmacological treatment has been compared to various kinds of psychosocial treatments, and until recently most investigators concluded, like May & Tuma (1974) , that pharmacotherapy is superior to other forms of treatment. Still, it should be emphasized that psychosocial treatment i n the form of milieu-therapy, psycho-therapy (both individual and group), family-therapy, occupational therapy, social care, &c., are important associations to and usually are facilitated by adequate psychopharmacological treatment.
Some recent studies have failed to confirm this statement, maintaining the association of drugs to be unnecessary if not deleterious to the successful outcome of adequate psychosocial treatment. Still, even the most drug-antagonistic investigators admit that drugs are useful initially for symptomreduction, even if at a later date they may be preventing good social functioning and interpersonal relations, achieved by psychosocial measures such as group therapy.
Most of these investigations, whether they give preference to one or the other type of treatment, are characterized by a good deal of investigatorbias and should be interpreted accordingly. A survey of studies on this controversial subject has recently been presented by Gunderson (1975) . As pointed out by Lehmann (1974) , there is no way to find out which patients are likely to have spontaneous remissions, so that one is obliged to accept either continuous administration of maybe unnecessary drugs or to run the risk of a possible relapse. Efforts to pin down subgroups of nonresponders to drug treatment have so far resulted in contradictory conclusions, and further research is needed. Hogarty et al. (1973) found a relapse rate after twelve months of 72.5 % for patients on placebo compared to only 32.6% for those on phenothiazines, but he also found that a subgroup of 20% of the patients on placebo had a good outcome.
During the last ten years, several papers have presented suggestive evidence for the fact that some schizophrenics actually do better without continuous administration of antipsychotic drugs (Kristjansen 1966 , Levine 1974 . In our laboratory Schi0rring (1972) has shown that in animal experiments neuroleptics may disrupt social interaction, suggesting that drugs in some cases may be increasing autism rather than reducing it, and a clinical study from our hospital (Gerlach & Luhdorf 1975) found a certain antiautistic effect of levodopa on younger male schizophrenics.
With this background we find it quite justified to interrupt long-term treatment and to recommend drug-free periods, as long as there are sufficient facilities for observation of the patients in these periods. Under such conditions we find it quite safe to give the patients drug holidays of even longer duration than recommended by Lehmann (1974) .
Evidently there are exceptions to the abovementioned general rules for the long-term treatment of schizophrenic patients. Some patients do feel better on a more sedative 'high-dosage' drug, and one has to admit that initial selection of the drug of choice for the individual patient may be quite impossible. For this reason it is an advantage for the psychiatrist working in the field of psychopharmacology to have an armamentarium of drugs at his disposal. A flexible drug-administration is for the benefit of the schizophrenic patient in long-term treatment. We do not agree with psychopharmacologists who claim that all neuroleptics are of equal value, whatever the schizophrenic symptoms may be.
Even if some patients do not feel unwanted sedation on the nonspecific high-dosage drugs, most of them do; for outpatients, in particular, it seems evident that sedation is rarely an advantage. In our opinion a successful resocialization is more frequently obtained when outpatients are treated with a more specific antipsychotic lowdosage drug.
Up till now there is no clinical evidence to support the assumption that the more specific drugs given in lower dosages are less toxic than drugs given in high dosages, as far as the central nervous system is concerned, but it has been mentioned that so far no verified case of persistent dyskinesia has been reported in patients treated exclusively with a depot neuroleptic (with the reservation that perphenazine enanthate was not included in this survey; Ayd 1973) . Recent investigations from our laboratories have shown a cell reduction approaching 20% in the corpus striatum of rats receiving perphenazine-enanthate 3.4 mg/kg every two weeks for twelve months. No cell reduction was found in the cortex of the animals (Pakkenberg et al. 1973) . Experiments along this line are being continued, including haloperidol and other neuroleptics. These preliminary results are mentioned in relation to the possible risk of provoking some form of irreversible organic brain damage by long-term administration of high dosages of neuroleptics.
It is against this background that some authors recommend drug holidays of various lengths; the lowest possible dosage of the given neuroleptic and only absolutely essential corrective anti-parkinsonian treatment for shorter periods (Lehmann 1974) .
A special pharmacological phenomenon, the neuroleptic-induced supersensitivity of the synaptic events, among others described by M0ller Nielsen (1974) might perhaps be interpreted clinically to the effect that neuroleptics should be given for limited periods, interrupted by drugfree intervals. Some of the above mentioned clinical investigations are pointing in the same direction. The conclusion of this would be that it may be advantageous in some cases to use a high dosage of neuroleptic drugs in order to obtain a rapid symptom reduction, but this kind of treatment should be done intermittently, in order to offer the patients maximal benefit and minimal risk of damage. Pakkenberg H, Fog R and Nilakantan B (1973) Psychopharmacologia (Berlin) 29, 329 Schiorring E (1972) Psychopharmacologia (Berlin) 26, Suppl. 117 
DISCUSSION
Dr G J Rockley (Manchester) said he would be interested in trying an increasing dosage scheme. However, there seemed to be a problem. Yesterday the meeting had heard that one goes through a middle range where side-effects are severe to an upper range where they disappear. In Dr Tanghe's account, however, some patients had to be restricted to the middle range because of apprehension about side-effects as the dose went higher. He was interested in the instructions to be given to the nurses as to when the dose should be pushed up and when the lower dose had to be maintained.
Dr A Reyntjens (Beerse) on behalf of Dr Tanghe said that this was a problem. In Dr Pacquay's study the nursing personnel had been briefed about this problem. Unfortunately this briefing had been omitted in Dr Tanghe's study.
If they were to repeat the study they would make sure they selected only those patients who were not too physically deteriorated. In Dr Tanghe's material, for example, perhaps one third of patients showed some physical deterioration or illness such as diabetes or hypertension. If the hypertensive patient started to become agitated and at the same time his pressure increased, the physician did not have the courage to keep increasing the dose. The best treatment was probably to do so but courage might fail.
Dr J S Howard (Fresno) said that-in his studies they began at quite low levels and did not encounter side-effects in the middle range with their chronic patients. There might be some difference between chronic and acute patients here, in that acute psychotics would go through this stage.
The individual with normal amobnts of dopamine which were converted to epinephrine and norepinephrine was below the psychotic level. In acute psychosis the dopamine might have been converted into norepinephrine and epinephrine, the patient coming dangerously close to extrapyramidal signs. In this situation a small amount of tranquillizer could bring on extrapyramidal side-effects. The chronic patient, especially one with chronically high levels of catecholamines, must have chronically higher levels of dopamine for their manufacture. In this case there might be a much larger margin of safety if the antipsychotic agent was given before the development of extrapyramidal signs. This would at least be Dr Howard's own explanation in the case of the chronic patient.
Dr E Shoenberg (London) wondered what criteria would speakers adopt, when faced with a chronic patient whose previous pharmacological history was unknown, in deciding whether to use haloperidol or a phenothiazine. She had also found a considerable pressure from nurses to give a little chlorpromazine with the haloperidol. Junior doctors in particular tended to prescribe whole cocktails of these two drugs. Dr Kristjansen said that the initial choice of drug will depend upon the physician's previous experience. Certainly haloperidol was quite safe as a first choice. There was little risk of toxic reaction. Chlorpromazine by contrast was rather more dangerous to use in high dosages, with a broader spectrum of toxic reactions than haloperidol. He personally had abandoned chlorpromazine more than ten years ago and had not missed it.
Dr E Shoenberg (London) asked what criteria, apart from questions of toxicity, could be used in selecting a patient for haloperidol rather than a phenothiazine in order to give him a better chance of mental recovery. Dr Kristjansen said that haloperidol covered a wide range of indications, although certainly some patients would do better on a phenothiazine, particularly in low dosages. He did not know of any method of deciding beforehand which patients would react better to one drug or the other. The decision depended upon clinical feeling which was rarely mentioned but constantly used. There had been attempts to establish psychological tests to make this decision but noone had yet arrived at a final conclusion.
